trial · primary record
Ublituximab
Relapsing Multiple Sclerosis (RMS)
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 1100 |
| Primary completion | 2032-05-31 |
| Primary endpoint | Annualized Relapse Rate (ARR) |
| Registry ID | NCT04130997 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:45.726Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04130997
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ublituximab · compound